



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 413/12, 413/14, 417/12 A61K 31/41, 31/445		A1	(11) International Publication Number: WO 93/20071 (43) International Publication Date: 14 October 1993 (14.10.93)
(21) International Application Number: PCT/EP93/00779 (22) International Filing Date: 26 March 1993 (26.03.93) (30) Priority data: 9206989.7 31 March 1992 (31.03.92) GB 9217827.6 21 August 1992 (21.08.92) GB 9221718.1 16 October 1992 (16.10.92) GB (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): OXFORD, Alexander, William [GB/GB]; Glaxo Group Research Limited, Park Road, Ware, Hertfordshire SG12 0DP (GB).		(74) Agents: BREWER, Christopher, Laurence et al.; Glaxo Holdings plc, Glaxo House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: SUBSTITUTED PHENYL CARBAMATES AND PHENYLUREAS, THEIR PREPARATION AND THEIR USE AS 5-HT ANTAGONISTS



(57) Abstract

Substituted phenylcarbamates and ureas of formula (I) wherein R¹ represents a hydrogen or a halogen atom, or a C₁₋₆alkyl, C₁₋₆alkoxy or hydroxy group; R² represents an oxadiazole or thiadiazole ring substituted by a group selected from C₁₋₆alkyl, C₃₋₇cycloalkyl, -CH₂C₂₋₅alkenyl, -CH₂C₂₋₅alkynyl, phenyl or benzyl; X represents NH or an oxygen atom; m represents 0, 1 or 2; R³ represents C₁₋₆alkyl, benzyl, -(CH₂)_nR⁴ or (a); R⁴ represents a group selected from cyano, hydroxyl, C₁₋₆alkoxy, phenoxy, C(=O)C₁₋₆alkyl, C(=O)C₆H₅, -CONR⁶R⁷, -NR⁶COR⁷, -SO₂NR⁶R⁷ or -NR⁶SO₂R⁷ (wherein each of R⁶ and R⁷ independently represent a hydrogen atom, a C₁₋₆alkyl or phenyl group); n represents 2 or 3; R⁵ represents COR⁸ or SO₂R⁸ (wherein R⁸ represents a hydrogen atom, a C₁₋₆alkyl or phenyl group); and quaternary ammonium derivatives, piperidine N-oxides and pharmaceutically acceptable salts and solvates thereof; which compounds are potent and specific antagonists of 5-hydroxytryptamine (5HT; serotonin).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LJ	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

1

SUBSTITUTED PHENYLCARBAMATES AND PHENYLUREAS, THEIR PREPARATION AND THEIR USE AS 5-HT ANTAGONISTS


This invention relates to substituted phenylcarbamates and ureas, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use.

European Patent Specification No. EP 0419397 describes compounds of formula



wherein

R^{10} is a group



where S is 2 or 3, t is 1 or 2, u is 1 to 3, v is 1-3 and

R^{40} and R^{50} are H, C_{1-7} alkyl or C_{3-6} cycloalkyl; and wherein R^{20} is an oxadiazole, substituted with C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-4} alkynyl, C_{3-7} cycloalkyl, benzyl, phenyl, C_{1-6} alkoxy, C_{1-6} alkylthio, amino or alkylamino; or

wherein R^{20} is $-C-R^{60} = N-O-R^{70}$, wherein R^{60} is hydrogen or methyl and R^{70} is C_{1-6} alkyl which may be substituted with C_{3-7} cycloalkyl;


and wherein R^{30} is hydrogen, halogen, nitro, substituted amine, trifluoromethyl, C_{1-6} alkyl or C_{1-6} alkoxy.

These compounds are stated to have 5-HT₂-receptor antagonist activity, anti-emetic activity and/or gastric motility enhancing activity.

The present invention relates to novel compounds which are potent and specific antagonists of 5-hydroxytryptamine (5-HT:serotonin).

SUBSTITUTE SHEET

Thus, the present invention provides substituted phenylcarbamates and ureas of formula (I):



wherein R¹ represents a hydrogen or a halogen atom, or a C₁₋₆alkyl, C₁₋₆alkoxy or hydroxy group;

10


R² represents an oxadiazole or thiadiazole ring substituted by a group selected from C₁₋₆alkyl, C₂₋₇cycloalkyl, -CH₂C₂₋₃alkenyl, -CH₂C₂₋₃alkynyl, phenyl or benzyl;

X represents NH or an oxygen atom;

m represents zero, 1 or 2;

15

R³ represents C₁₋₆alkyl, benzyl, -(CH₂)_nR⁴ or



R⁴ represents a group selected from cyano, hydroxyl, C₁₋₆alkoxy, phenoxy, C(=O)C₁₋₆alkyl, C(=O)C₆H₅, -CONR⁶R⁷, -NR⁶COR⁷, -SO₂NR⁶R⁷ or -NR⁶SO₂R⁷ (wherein each of R⁶ and R⁷ independently represent a hydrogen atom, a C₁₋₆alkyl or phenyl group);

20

n represents 2 or 3;

R⁵ represents COR⁸ or SO₂R⁸ (wherein R⁸ represents a hydrogen atom, a C₁₋₆alkyl or phenyl group);

25

and quaternary ammonium derivatives, piperidine N-oxides and pharmaceutically acceptable salts and solvates thereof.

Suitable pharmaceutically acceptable salts of the compounds of general formula (I) include acid addition salts formed with pharmaceutically acceptable organic or inorganic acids for example, hydrochlorides, hydrobromides, sulphates, alkyl- or arylsulphonates


30

(e.g. methanesulphonates or p-toluenesulphonates), phosphates, acetates, citrates, succinates, tartrates, fumarates and maleates.

Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts. The solvates may, for example, be hydrates.


References hereafter to a compound according to the invention includes both compounds of formula (I) and their quaternary ammonium derivatives, piperidine N-oxides and pharmaceutically acceptable acid addition salts together with pharmaceutically acceptable solvates.

Quaternary ammonium derivatives of compounds of formula (I) are compounds of formula




where Q represents C₁₋₆alkyl (e.g. methyl).

Piperidine N-oxides of compounds of formula (I) are compounds of formula



The oxadiazole or thiadiazole ring R² in the compounds of formula (I) may be a 1,2,4-oxadiazol-5-yl or -3-yl or 1,2,4-thiadiazol-5-yl or -3-yl, i.e.

4



where W is -O- or -S-.

When the oxadiazole or thiadiazole ring is substituted, the substituent will be attached to the free carbon atom in the oxadiazole or thiadiazole ring.

All optical isomers of compounds of general formula (I) and their mixtures including the racemic mixtures thereof, and all the geometric isomers of compounds of formula (I), are embraced by the invention.

Referring to the general formula (I), a C_{1-6} alkyl group may be a straight chain or branched chain alkyl group, for example, methyl, ethyl, propyl, prop-2-yl, butyl, but-2-yl, 2-methylprop-2-yl, pentyl, pent-3-yl or hexyl. A $-CH_2C_{2-3}$ alkenyl group may be, for example, a propenyl or butenyl group. A $-CH_2C_{2-3}$ alkynyl group may be, for example, a prop-2-ynyl group. C_{3-7} cycloalkyl may be, for example, cyclopropyl, cyclobutyl or cyclohexyl.

When R^1 represents a halogen atom this may be, for example, a fluorine, chlorine, bromine or iodine atom. R^1 may be attached at any vacant position on the phenyl ring. For example, R^1 may be para to the -NH- substituent or para to R^2 .

A preferred class of compounds of formula (I) is that in which R^1 represents a hydrogen atom, a halogen (e.g. fluorine) atom or a C_{1-6} alkyl (e.g. methyl) or C_{1-6} alkoxy (e.g. methoxy) group. Furthermore, when R^1 represents a halogen (e.g. fluorine) atom or a C_{1-6} alkyl (e.g. methyl) or C_{1-6} alkoxy (e.g. methoxy) group this is preferably attached para to the -NH- substituent or para to R^2 .


Another preferred class of compounds of formula (I) is that in which R^2 represents an oxadiazole or thiadiazole ring substituted by a C_{1-6} alkyl (e.g. methyl, prop-2-yl or butyl), C_{3-7} cycloalkyl (e.g. cyclopropyl), phenyl or benzyl group. for example a

SUBSTITUTE SHEET

5

1,2,4-oxadiazol-5-yl substituted in the 3-position by a C_{1-6} alkyl (e.g. methyl, prop-2-yl or butyl), C_{3-7} cycloalkyl (e.g. cyclopropyl), phenyl or benzyl group, or 1,2,4-oxadiazol-3-yl substituted in the 5-position by a C_{1-6} alkyl (e.g. methyl) group or a 1,2,4-thiadiazol-5-yl substituted in the 3-position by a C_{1-6} alkyl (e.g. methyl) group.

- 5 A preferred class of compounds of formula (I) is that in which R^3 represents C_{1-6} alkyl (e.g. prop-2-yl), benzyl,



- 10 (where R^5 preferably represents SO_2R^4 , e.g. SO_2Me) or, more preferably, $-(CH_2)_nR^4$.

When R^3 represents $-(CH_2)_nR^4$, a preferred class of compounds of formula (I) is that in which n represents 3 or, more preferably, 2 and R^4 represents a $-C_{1-6}$ alkoxy (e.g. methoxy), $-CONR^6R^7$ (e.g. $CONH_2$), $-NR^6COR^7$ (e.g. $NHCOMe$), $-SO_2NR^6R^7$ (e.g. SO_2NHMe) or $-NR^6SO_2R^7$ (e.g. $NHSO_2Me$ or $NMeSO_2Me$) group.


- 15 A further preferred class of compounds of formula (I) is that in which m represents 1.

Also preferred is the class of compounds of formula (I) where X represents an oxygen atom.

- A preferred group of compounds of formula (I) is that in which R^1 represents a hydrogen or halogen (e.g. fluorine) atom, a C_{1-6} alkyl (e.g. methyl) or C_{1-6} alkoxy (e.g. methoxy) group (e.g. a hydrogen atom or a fluorine atom or methyl or methoxy group para to the $-NH-$ substituent or para to R^2); R^2 represents an oxadiazole or thiadiazole ring substituted by a C_{1-6} alkyl (e.g. methyl, prop-2-yl or butyl), C_{3-7} cycloalkyl (e.g. cyclopropyl), phenyl or benzyl group, for example, a 1,2,4-oxadiazol-5-yl substituted in the 3-position by a C_{1-6} alkyl (e.g. methyl, prop-2-yl or butyl), C_{3-7} cycloalkyl (e.g. cyclopropyl), phenyl or benzyl group, a 1,2,4-oxadiazol-3-yl substituted in the 5-position by a C_{1-6} alkyl (e.g. methyl) group, or a 1,2,4-thiadiazol-5-yl substituted in the 3-position by a C_{1-6} alkyl (e.g. methyl) group; X represents NH or, more preferably, an oxygen atom; m represents zero, 2 or, more preferably, 1; R^3 represents C_{1-6} alkyl (e.g. prop-2-yl), benzyl,

30

SUBSTITUTE SHEET



(where R⁵ preferably represents SO₂R⁴, e.g. SO₂Me) or, more preferably, -(CH₂)_nR⁴ where n represents 3 or, more preferably, 2 and R⁴ represents C₁₋₆alkoxy (e.g. methoxy), -CONR⁶R⁷ (e.g. CONH₂), -NR⁶COR⁷ (e.g. NHCOMe), -SO₂NR⁶R⁷ (e.g. SO₂NHMe) or -NR⁶SO₂R⁷ (e.g. NHSO₂Me or NMeSO₂Me).

Specific compounds according to the invention are:-

10 [1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

[1-[2-[(Methylsulphonyl)methylamino]ethyl]-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

15 [1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidiny]methyl[2-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl]carbamate;

20 [1-[2-(Methylsulphonyl)amino]ethyl]-4-piperidiny]methyl[4-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

[1-[2-[(Methylamino)sulphonyl]ethyl]-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

25 [1-(2-Methoxyethyl)-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

[1-[3-[(Methylsulphonyl)amino]propyl]-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

30

[1-[2-(Acetylamino)ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate di-p-toluoyl-1-tartrate;

5 N-[2-[4-[2-[[[2-(3-Methyl-1,2,4-oxadiazol-5-yl)phenyl]amino]carbonyl]amino]ethyl]-1-piperidinyl]ethyl]methanesulphonamide;

1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

10 [1-(3-Amino-3-oxopropyl)-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

[1'-(Methylsulphonyl)[1,4'-bipiperidin]-4-yl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

15

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[5-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

20 N-[2-[4-[[[2-(3-Methyl-1,2,4-oxadiazol-5-yl)phenyl]amino]carbonyl]amino]methyl]-1-piperidinyl]ethyl]methanesulphonamide;

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

25 [1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]phenyl]carbamate;

30

8

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidiny]methyl[2-[3-(phenylmethyl)-1,2,4-oxadiazol-5-yl]phenyl]carbamate;

5 [1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidiny]methyl[2-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]phenyl]carbamate monohydrochloride;

10 [1-(1-Methylethyl)-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

[1-(1-Methylethyl)-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

15

N-[2-[4-[[[2-(5-Methyl-1,2,4-oxadiazol-3-yl)phenyl]amino]carbonyl]amino]methyl]-1-piperidiny]ethyl]methanesulphonamide;

20 [1-[2-[(Methylsulphonyl)methylamino]ethyl]-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

N-(3-Methyl-1,2,4-oxadiazol-5-yl)-N'-[2-[1-(phenylmethyl)-4-piperidiny]ethyl]urea;

25 1-(Phenylmethyl)-4-piperidiny [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

[1-(Phenylmethyl)-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

30 and quarternary ammonium derivatives, piperidine N-oxides and pharmaceutically acceptable salts and solvates thereof.

SUBSTITUTE SHEET

The compounds of the invention are antagonists of 5-HT both in vitro and in vivo and are thus of use in the treatment of conditions mediated by 5-HT.

In particular the compounds of the invention inhibit the 5-HT induced contraction of guinea-pig colon (essentially following the general procedure described by C.J. Elwood et al in Br. J. Pharmac., 1990, 100, (Proc.Suppl.) 485P and Eur. J. Pharmac., 1991, 196, 149-155 in the presence of ondansetron and methysergide) and the 5-HT-induced secretion in rat colon (as described by K T Bunce et al in Br.J. Pharmac., 1991, 102, 811-816), and are thus useful in the treatment of 5-HT mediated disorders in which there is a disturbance of gastrointestinal function. Conditions involving disturbance of intestinal function include for example irritable bowel syndrome and its associated pain, excessive gastrointestinal secretion, and/or diarrhoea for example diarrhoea associated with excessive gastrointestinal secretion, cholera infection and carcinoid syndrome. The compounds of the invention may also be useful in the treatment of emesis.

The compounds of the invention have been shown to be 5-HT₄ antagonists in vitro as demonstrated by their ability to inhibit the 5-HT-induced relaxation of the rat oesophagus preparation (essentially following the general procedure described by J J Reeves et al in Br. J Pharmac., 1989, 98, (Proc.Suppl.), 800P and 1991, 103, 1067-1072) and are thus of use in the treatment of conditions capable of amelioration by antagonism of such receptors. 5-HT₄ receptors have been found in, for example, the digestive and urinary tracts, brain and cardiovascular system of mammals, including man, and are thus believed to be associated with conditions involving the digestive and urinary tracts (e.g. urinary incontinence), cardiovascular system and CNS disorders.

Thus the compounds of the invention may also be useful in the treatment of movement disorders (e.g. Parkinsonism), psychoses such as schizophrenia, mania, dementia or other cognitive disorders e.g. Alzheimer's disease; depression; and dependency on drugs or substances of abuse.

The compounds of the invention have been shown to be active in the rat social interaction test as described by B J Jones et al in Br J Pharmac., 1988, 93, 985-93 and are thus of use in the treatment of anxiety.

In a further aspect the invention therefore provides a compound of formula (I) or a quaternary ammonium derivative, piperidine N-oxide or a pharmaceutically acceptable salt or solvate thereof for use in therapy, in particular in human medicine. It will be appreciated that use in therapy embraces but is not necessarily limited to use of a compound of the invention as an active therapeutic substance.

There is also provided as a further aspect of the invention the use of a compound of formula (I) or a quaternary ammonium derivative, piperidine N-oxide or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for use in the treatment of conditions mediated by 5-hydroxytryptamine, in particular conditions capable of amelioration by antagonism of 5-HT₁ receptors.

In an alternative or further aspect there is provided a method for the treatment of a mammal, including man, comprising administration of an effective amount of a compound of formula (I) or a quaternary ammonium derivative, piperidine N-oxide or a pharmaceutically acceptable salt or solvate thereof in particular in the treatment of conditions mediated by 5-hydroxytryptamine, in particular conditions capable of amelioration by antagonism of 5-HT₁ receptors.

It will be appreciated that reference to treatment is intended to include prophylaxis as well as the alleviation of established symptoms. Compounds according to the invention may be administered as the raw chemical but the active ingredient is preferably presented as a pharmaceutical formulation.

Accordingly, the invention also provides a pharmaceutical composition comprising a compound of formula (I) or a quaternary ammonium derivative, piperidine N-oxide or a pharmaceutically acceptable salt or solvate thereof and formulated for administration by any convenient route. Such compositions are preferably in a form adapted for use in medicine, in particular human medicine, and can conveniently be formulated in conventional manner using pharmaceutically acceptable carriers.

Thus the compounds according to the invention may be formulated for oral, buccal, parenteral, topical, implant or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycolate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

Preparations for oral administration may also be suitably formulated to give "pulsed release" i.e. rapid release of the active ingredient after an initial time delay. Such pulsed release formulations may further be enterically coated to allow targeting of drugs to the colon for either a direct local action, or to provide a preferred site for drug delivery.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

The compounds of the invention may be formulated for parenteral administration by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising

and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

The compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

For intranasal and pulmonary administration, the compounds according to the invention may be formulated as solutions or suspensions for administration via a suitable metered or unit dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.


For topical and percutaneous administration, the compounds according to the invention may be formulated as solutions, suspensions, creams or ointments and be included in systems that provide controlled release.

A proposed dose of the compounds of the invention for administration to man (of approximately 70kg body weight) is 1mg to 100mg, of the active ingredient per unit dose expressed as the weight of free base, which could be administered, for example, 1 to 4 times per day. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient and the precise dosage will be ultimately at the discretion of the attendant physician or veterinarian. The dosage will also depend on the route of administration.


The compounds of the invention may, if desired, be administered in combination with one or more other therapeutic agents and formulated for administration by any convenient route in a conventional manner. Appropriate doses will be readily appreciated by those skilled in the art.

Compounds of formula (I), and quaternary ammonium derivatives, piperidine N-oxides and pharmaceutically acceptable salts or solvates thereof, may be prepared by the general methods outlined hereinafter. In the following description, the groups R^1 to R^3 , X and m are as previously defined for compounds of formula (I) unless otherwise stated.

According to a first general process (A), a compound of formula (I) may be prepared by reacting a compound of formula (II) or (III):



or a protected derivative thereof, wherein Y represents a leaving atom or group such as a halogen (e.g. chlorine) atom, with a compound of formula (IV):




where M is NH_2 , OH or an activated derivative thereof (e.g. an alkali metal (e.g. lithium) alkoxide), optionally in the presence of a strong acid such as methanesulphonic acid.

The reaction is conveniently effected in an inert organic solvent such as an ether (e.g. tetrahydrofuran) or a halogenated hydrocarbon (e.g. dichloromethane) at a temperature between $-80^\circ C$ and the reflux temperature of the solvent. Alternatively, the reaction may take place by fusion in the absence of any solvent at an elevated temperature such as $100-200^\circ C$, e.g. 140 to $175^\circ C$.



According to another general process (B), a compound of formula (I) may be prepared by alkylating a compound of formula (V):

14

5




or a protected derivative thereof, with a compound of formula (VIa) or (VIb):



10 wherein L represents a leaving atom or group such as a halogen (e.g. chlorine, bromine or iodine) atom, or an acyloxy (e.g. trifluoroacetyloxy) or a sulphonyloxy (e.g. p-toluenesulphonyloxy) group and R^4 is an electron withdrawing group, i.e. $\text{C(O)C}_{1-6}\text{alkyl}$, $\text{C(O)C}_6\text{H}_5$, CONR^6R^7 , $\text{SO}_2\text{NR}^6\text{R}^7$ (where R^6 and R^7 are as defined in formula (I)); or a protected derivative thereof, in the presence of a base such as a tertiary
15 amine (e.g. diisopropylethylamine or triethylamine).

The reaction is conveniently effected in an inert organic solvent such as acetonitrile, a substituted amide (e.g. dimethylformamide) or an aromatic hydrocarbon (e.g. toluene), at an elevated temperature, for example at the reflux temperature of the solvent.

Alternatively compounds of formula (V) may be reacted with a compound of formula
20 (VIc)




in the presence of a reducing agent.

Suitable reducing agents include borohydrides such as sodium cyanoborohydride or sodium triacetoxyborohydride. Suitable solvents will depend upon the reducing agent
25 used, but may include alcohols, for example, methanol or ethanol, halogenated hydrocarbons, for example, 1,2-dichloroethane or ethers, for example, diethyl ether or tetrahydrofuran. The reaction conveniently takes place at ambient temperature.


According to another general process (C), a compound of formula (I) where R^2 is a 1,2,4-oxadiazol-3-yl group may be prepared by reacting a compound of formula (VII)

30

15




where Z is C₁₋₆alkoxy (e.g. methoxy), with a compound of formula (VIII)



where R⁹ is a substituent as defined for R¹, in the presence of a strong base such as sodium hydride.

The reaction conveniently takes place in a suitable solvent such as an ether (e.g. tetrahydrofuran) at an elevated temperature, such as the reflux temperature of the reaction mixture.


According to another general process (D), a compound of formula (I) where R² is a 1,2,4-thiadiazol-5-yl group may be prepared by reacting a compound of formula (IX)



where R⁹ is as defined above, with hydroxylamine-O-sulfonic acid, optionally in the presence of a base such as pyridine.

The reaction conveniently takes place in a suitable solvent such as an alcohol (e.g. methanol) at ambient temperature.

According to a further general process (E), a compound of formula (I), where R¹ represents a group -(CH₂)₆R⁴ where R⁴ is a group NH-SO₂R⁷, may be prepared by reacting a compound of formula (X)



with a compound (XI)



10 where hal is a halogen (e.g. chlorine) atom, in the presence of a base (e.g. pyridine).

The reaction conveniently takes place in a suitable solvent such as a halogenated hydrocarbon (e.g. dichloromethane) at ambient temperature

According to another general process (F), a compound of formula (I) may be converted into another compound of formula (I) using conventional techniques.

15 Thus, for example, compounds of formula (I) where R^3 represents a group containing an -NH- moiety may be converted into another compound of formula (I) wherein R^3 contains a -N(C₁₋₆alkyl)- moiety (e.g. -N(CH₃)-) using a suitable alkylating agent such as an alkyl iodide e.g. methyl iodide) as described above. The reaction conveniently takes place in a suitable solvent such as an ether (e.g. tetrahydrofuran) at ambient temperature and in the presence of a strong base such as sodium hydride.

20 Also, quaternary ammonium salts of compounds of formula (I) may be prepared by reacting non-quaternary compounds of formula (I) with a suitable quaternising agent such as Q-L (where L is a leaving group as defined above e.g. a halogen (e.g. iodine) atom and Q is as defined above). The reaction conveniently takes place in a suitable solvent such as a chlorinated hydrocarbon (e.g. chloroform) at ambient temperature.


25 Piperidine N-oxides of compounds of formula (I) may be prepared by reacting an appropriate piperidine compound of formula (I) with a suitable oxidising agent such as 3-chloro peroxybenzoic acid. Oxidation conveniently takes place in a suitable solvent such as a halogenated hydrocarbon (e.g. chloroform) at ambient temperature.

30

It should be appreciated that in the above transformations it may be necessary or desirable to protect any sensitive groups in the molecule of the compound in question to avoid undesirable side reactions. For example when R^3 represents a hydroxyl group it may be necessary to protect the hydroxyl group, for example with an arylmethyl (e.g. benzyl or trityl) group. It may also be necessary to protect compounds where R^3 contains other sensitive groups such as an amine group. Such groups may be protected for example using an acyl group (e.g. benzyloxycarbonyl) or a silyl group (e.g. trimethylsilyl).

Thus according to another general process (G), a compound of general formula (I) may be prepared by the removal of any protecting groups from a protected form of a compound of formula (I). Deprotection may be effected using conventional techniques such as those described in 'Protective Groups in Organic Synthesis 2nd Ed.' by T. W. Greene and P G M Wuts (John Wiley and Sons, 1991).


Compounds of formula (II) where Y is chlorine may be prepared, for example, by reacting a compound of formula (XII) :



with phosgene.


Compounds of formula (III) are either known or may be prepared from known compounds by conventional procedures. For example, the compounds may be prepared by treatment of the corresponding aniline of formula (XII) with phosgene followed by a strong base such as triethylamine.

Compounds of formula (V) may be prepared, for example, by reacting a compound of formula (XIII)





wherein R^{10} is a C_{1-6} alkyl (e.g. methyl) group with a chloroformate (e.g. 1-chloroethyl chloroformate, vinylchloroformate or ethylchloroformate) at an elevated temperature, with subsequent heating of the reaction mixture at reflux temperature with an alcohol (e.g. methanol).

5 Compounds of formula (XII) may be prepared according to the method of general process (A), by reacting a compound of formula (II) with a compound of formula (XIV)




10 where M is as defined above and R^{11} is a C_{1-6} alkyl (e.g. methyl) group.

Compounds of formula (VII) may be prepared by reacting compounds of formula (XV) or (XVI)




15 where Y and Z are as defined above, with a compound of formula (IV) as defined above, under conditions as described above for process (A).

20 Compounds of formula (IX) may be prepared by reacting a compound of formula (XVII)



25 with a compound of formula (XVIII)


30



where R^9 is as defined above.

The reaction conveniently takes place in a suitable solvent such as an amide (e.g. dimethylformamide) at ambient temperature.

Compounds of formula (XVII) may be prepared by reacting compounds of formulae (XIX) or (XX)




or a protected derivative thereof, where Y is as defined above, with a compound of formula (IV) as defined above, under conditions as described above for process (A), followed by removal of any protecting groups present.

Compounds of formula (X) may be prepared by reacting a compound of formula (V) with an appropriate alkylating agent under conditions as described in process (B).

Compounds of formulae (V), (VII), (IX), (X), (XIII) and (XVIII) are novel and therefore form a further feature of the invention. The remaining compounds are either known, or may be prepared from known compounds by conventional procedures.

In addition, compounds of formula (IV) may be prepared by reduction of the corresponding compounds of formula (XXI)



wherein A^- represents an associated anion such as a halide (e.g. bromide) anion and M is as defined above. Reduction may be conveniently effected by hydrogenation in the

presence of a suitable catalyst, such as rhodium on alumina, in the presence of a suitable solvent, for example under aqueous conditions.

Compounds of formula (XXI) may be prepared by alkylation of 4- pyridine methanol or 4-pyridine methylamine (in which the amino group has been protected with a suitable protecting group) using a suitable alkylating agent of formula (VIa) as defined
5 hereinbefore. The reaction conveniently takes place in the presence of sodium iodide in a suitable solvent such as an alcohol (e.g. isopropanol) at the reflux temperature of the solvent.

Where it is desired to isolate a compound of the invention as a salt, for example a
10 physiologically acceptable salt, this may be achieved by reacting the compound of formula (I) in the form of the free base with an appropriate acid, preferably with an equivalent amount, in a suitable solvent such as an alcohol (e.g. ethanol or methanol), an ester (e.g. ethyl acetate) or an ether (e.g. tetrahydrofuran).

Physiologically acceptable salts may also be prepared from other salts, including
15 other physiologically acceptable salts, of the compound of formula (I) using conventional methods.

The compounds of the invention may readily be isolated in association with solvent molecules by crystallisation from or evaporation of an appropriate solvent to give the corresponding solvates.

20 Individual enantiomers of the compounds of the invention may be obtained by resolution of a mixture of enantiomers (e.g. a racemic mixture) using conventional means, such as an optically active resolving acid; see for example 'Stereochemistry of Carbon Compounds' by E.L.Eliel (McGraw Hill, 1962) and 'Tables of Resolving Agents' by S. H. Wilen.

25 The various general methods described above may be used for the introduction of the desired groups at any stage in the stepwise formation of the required compound, and it will be appreciated that these general methods can be combined in different ways in such multi-stage processes. The sequence of the reactions in multi-stage processes should of course be chosen so that the reaction conditions used do not affect groups in the molecule
30 which are desired in the final product.

The invention is further illustrated by the following Intermediates and Examples. All temperatures are in °C. Thin layer chromatography (t.l.c.) was carried out on silica, and flash column chromatography (FCC) on silica (Merck 9385). Solvent System A as used for chromatography denotes dichloromethane:ethanol:0.88 ammonia solution.

5 Organic extracts were dried, where indicated, over magnesium sulphate.

Intermediate 1

[2-(3-Methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl chloride

A solution of 2-(3-methyl-1,2,4-oxadiazol-5-yl)benzenamine (1.0g) in dry
10 dichloromethane (20ml) was added dropwise to a 0° solution of phosgene (14.1ml, 20% in toluene) in dry dichloromethane (50ml) under a nitrogen atmosphere. After addition the reaction mixture was allowed to slowly attain room temperature and stirred for 4h. Nitrogen was bubbled through the resulting mixture for 16h. Dichloromethane was added to the resultant precipitate and the solution was evaporated to give the title compound
15 (1.322g), ν_{max} (Nujol) 2800-2500, 1782 (NCO-Cl), 1631 (C=N), 1501 (NH), 769 (aromatic) cm^{-1} .

Intermediate 2

N-[2-[4-(Hydroxymethyl)-1-piperidinyl]ethyl]methanesulphonamide

20 4-Piperidine methanol (1.60g) was dissolved in dry acetonitrile (40ml), N,N-diisopropylethylamine (5ml) was added, followed by N-(2-bromoethyl)methanesulphonamide (2.95g) in acetonitrile (10ml), and the resulting mixture heated at reflux for 2h. The solvent was removed in vacuo to leave a gum. This was purified by FCC eluting with System A (75:8:1) to give the title compound (1.80g) as
25 a solid, m.p. 81-82°.

Intermediate 3

Methyl 2-[(chlorocarbonyl)amino]benzoate

A solution of methyl anthranilate (6.0g) in dichloromethane (50ml) was added dropwise
30 over 15min to a 0° solution of phosgene (20% in toluene, 100ml) in dichloromethane

(50ml) under a nitrogen atmosphere. After addition the resulting opaque solution was stirred at room temperature for 5h before concentrating to dryness to give the title compound as a white solid (8.0g), m.p. 80-82°.

Similarly prepared:

5

Intermediate 4

[4-Methoxy-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamoyl chloride (2g), mp> 320° (dec).

From [4-methoxy-2-(3-methyl-1,2,4-oxadiazol-5-yl)]benzenamine (1.5g)

10

Intermediate 5

Methyl 2-[[[1-[2-[(methanesulphonyl)amino]ethyl]-4-piperidinyl]methoxy]carbonyl]amino]benzoate

A well mixed powder phase of methyl 2-[(chlorocarbonyl)amino] benzoate and
15 N-[2-[4-(Hydroxymethyl)-1-piperidinyl] ethyl]methanesulphonamide (2.43g) under a nitrogen atmosphere was lowered into a pre-heated oil bat at 150°. After 35 min the mixture was cooled and dissolved in dichloromethane (50ml) and 8% sodium bicarbonate solution (50ml). The aqueous was separated and further extracted dichloromethane (2x30ml). Combined organics were washed with saturated brine (30ml), dried and
20 concentrated to give a viscous oil (3.3g). FCC using System A (95:5:0.5) as eluant afforded the title compound as a white solid (1.82g) m.p. 106-108°.

Intermediate 6

4-Methoxy-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzenamine

25 Sodium hydride (594mg) was added to a stirred suspension of acetamide oxime (1.0g) and 4 molecular sieves (4g) in dry tetrahydrofuran (50ml) under nitrogen. The mixture was heated at 60° for 30min then allowed to cool to room temperature. A solution of 2-amino-5-methoxybenzoic acid.methyl ester (2.0g) in dry tetrahydrofuran (20ml) was added and the mixture stirred at reflux for 2.5h. The suspension was allowed to cool.
30 filtered and the filtrate evaporated to give the title compound as a yellow solid (1.64g)

T.l.c. (cyclohexane:ethyl acetate 9:1) Rf=0.20

Similarly prepared:

5 Intermediate 7

4-Methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzenamine (1.19g), m.p. 92.5-95.5°

From acetamide oxime (821mg) and 2-amino-5-methylbenzoic acid, methylester (1.5g) with further purification by FCC using 10% ethyl acetate in cyclohexane as eluant.

10 Intermediate 8

5-Fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzenamine

From acetamide oxime (3.52g) and 2-amino-4-fluorobenzoic acid, ethyl ester (6.96g), to give a brown-green solid (ca.6g) which was further purified by FCC using 20% diethyl ether in cyclohexane as eluant to give an off-white solid (3.4g). Trituration of a 900mg portion in cyclohexane (9ml) gave the title compound (520mg).

Repeating the trituration on all crude material gave further title compound as a white powder (2.184g) m.p. 146.5-148.2°.

Intermediate 9

20 4-Piperidinylmethyl [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate hydrochloride
[1-[(Phenylmethyl)-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]

carbamate (300mg) and 1-chloroethyl chloroformate (1.32ml) were heated together at 50° for 2h. Methanol (1.8ml) was added and the mixture heated at reflux for 0.5h. The solvent was removed in vacuo to give a yellow solid (300mg) which was purified by FCC with eluant System A (90:10:1). Further elution with System A (25:10:1) afforded the free base of the title compound as a solid (217mg).

T.l.c. (System A 25:10:1) Rf 0.46.

The free base was dissolved in methanol (10ml) and maleic acid (71mg) in methanol (2ml) was added. The solvent was removed in vacuo and the residual oil was triturated with ether to yield a brown solid (237mg). The solid was converted to the free base using

column chromatography with System A (70:30:3) as eluant to yield the free base (155mg) as a clear oil.

T.l.c (System A, 70:30:3) Rf 0.29. The free base was dissolved in dichloromethane and ethereal hydrogen chloride was added. Concentration to dryness followed by trituration with ether gave the title compound as a cream solid (136mg).

Analysis Found

C,52.3; H,5.8; N,15.1;

$C_{16}H_{20}N_4O_3 \cdot HClH_2O$ requires:

C,51.8; H,6.2; N,15.1%

Water analysis shows 1.61% H_2O w/w

10 Intermediate 10

4-Piperidinyl [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate

A solution of 1-(phenylmethyl)-4-piperidinyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (1.0g) in 1-chloroethyl chloroformate (5.5ml) was stirred at 50° under nitrogen for 3h. Methanol (6.2ml) was added and the mixture stirred at reflux for a further 2h. The solvent was removed in vacuo to give an off-white solid (~900mg). FCC with System A (100:10:1) as the eluent gave the title compound as a white solid (500mg) m.p. 141-2°.

Similarly prepared:

20

Intermediate 11

N'-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-N'-[2-(4-piperidinyl)ethyl]urea (450mg)

T.l.c. (System A, 25:10:1), Rf=0.25

From N-(3-Methyl-1,2,4-oxadiazol-5-yl)-N'-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl] urea (1.25g). A sample of the free-base above (150mg) was dissolved in dry dichloromethane (2ml) and treated with an excess of ethereal hydrogen chloride solution. The solvent was removed in vacuo and the residue triturated with dry ether (5x5ml) to give the hydrochloride salt of the title compound as a light brown solid (160mg), m.p. 129-132°

30

Intermediate 12

N-[2-[[[1-(Dimethylamino)ethylidene]amino]thioxomethyl] phenyl]acetamide

N-[2-(Aminothioxomethyl)phenyl]-acetamide (3.500g) was dissolved in dimethylformamide (60ml). Dimethyl acetamide dimethyl acetal (6.5ml) was added and the dark red solution stirred under a nitrogen atmosphere at room temperature for 5h. Concentration in vacuo gave the title compound as a red oil, (5.1g).

T.l.c (System A 300:8:1) Rf 0.35

Intermediate 13

10 N-[2-(3-Methyl-1,2,4-thiadiazol-5-yl)phenyl]acetamide

N-[2-[[[1-(Dimethylamino)ethylidene]amino]thioxomethyl] phenyl]acetamide (5.1g) and hydroxylamine-o-sulfonic acid (3.048g) were dissolved in methanol (60ml). Pyridine (2.9ml) was added and the resulting solution was stirred under nitrogen at room temperature for 24h. Concentration in vacuo gave a brown solid. This was separated between sodium carbonate solution (60ml) and dichloromethane (50ml), the aqueous extracted with fresh dichloromethane (5x30ml) and the combined organic extracts dried. Concentration in vacuo gave a brown solid (3.3g) which was dissolved in ethanol (20ml), and purified by FCC using cyclohexane:ethyl acetate (60:40) as eluant to give the title compound as a yellow- brown solid (2.98g). T.l.c. (cyclohexane:ethyl acetate, 60:40) Rf 0.55.

Intermediate 14

2-(3-Methyl-1,2,4-thiadiazol-5-yl)benzenamine

N-[2-(3-Methyl-1,2,4-thiadiazol-5-yl)phenyl]acetamide (1.487g) was dissolved in Claisen's alkali (6.3M KOH in methanol, 12ml) and refluxed under a nitrogen atmosphere for 16h, then cooled and extracted with ethyl acetate (3x40ml). The combined organic extracts were washed with sodium chloride solution (10ml), dried and concentrated in vacuo to give an orange powder (1.1g). FCC using cyclohexane:ethyl acetate (4:1) as eluant gave the title compound as a yellow solid. (302mg) T.l.c (cyclohexane:ethyl:acetate, 4:1) Rf 0.6.

Intermediate 15[2-(5-Methyl-1,2,4-oxadiazol-3-yl)phenyl]carbamoyl chloride

A solution of 2-(5-methyl-1,2,4-oxadiazol-3-yl)benzeneamine (1.0g) in dry
5 dichloromethane (20ml) was added dropwise to a solution of phosgene (14.1ml) in
dichloromethane (50ml) at 0° under a nitrogen atmosphere. The opaque solution was then
allowed to slowly attain room temperature and stirred for 17h. The reaction mixture was
concentrated under vacuo to give a pale yellow solid (1.3g).

m.p. 165° dec.

Intermediate 16[1-(2-Aminoethyl)-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]
carbamate

A solution of 4-piperidinylmethyl [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate
15 (200mg), 2-bromoethylamine hydrobromide (130mg) and diisopropylethylamine (0.33ml)
in dry acetonitrile (10ml) was stirred at reflux under nitrogen for 6h. The solvent was
removed in vacuo to give a semi-solid (~675mg). FCC using System A (75:10:1) as the
eluent gave the title compound as a colourless oil (158mg).

T.l.c. (System A 75:10:1) Rf 0.35.

Example 1[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-
oxadiazol-5-yl)phenyl]carbamate

A solution of phosgene in toluene (12.5%w/v; 100ml) was added to 2-
25 (3-methyl-1,2,4-oxadiazol-5-yl)benzenamine (2.5g) and the heterogeneous mixture was
stirred at reflux under nitrogen for 2h. Additional toluene (70ml) was added and the
mixture was stirred at reflux for a further 30min. After cooling, the reaction was
evaporated to dryness and the resulting solid was treated with N-
[2-[4-(hydroxymethyl)-1-piperidinyl]ethyl] methanesulphonamide (3.1g) and
30 1,2-dichlorobenzene (mol. sieve-dried, 100ml) and stirred at 120° under nitrogen for

18½h. The mixture was cooled to ca. 10° and diluted with cyclohexane (100ml). The solid was collected by filtration, mixed with 8% sodium bicarbonate solution and extracted with 10% ethanol in dichloromethane (1x100ml then 6x50ml). The combined organic extract was dried (Na₂SO₄) and evaporated to dryness and the residue purified by
 5 FCC eluting with System A (100:8:1) to give a beige solid which material was recrystallised from cyclohexane:ethyl acetate (ca. 140ml:40ml) to give the title compound (1.65g)

as white microneedles, m.p. 129-130°

Analysis Found:

C,52.4; H,6.4; N,15.2;

10 C₁₉H₂₇N₅O₅.S.0.18C₄H₄O₂ requires

C,52.2; H,6.3; N,15.45%

Example 2

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (Z)-2-butenedioate salt (1:1)

15 [1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (1.541g) was dissolved in warm methanol (30ml) and treated with a methanolic solution (5ml) of maleic acid (0.409g). The resulting solution was evaporated to dryness. The cream solid was triturated with warm ethyl acetate and dried in vacuo to give the title compound (1.36g), m.p. 163-164°.

20 Analysis Found:

C,49.7; H,5.6; N,12.45;

C₁₉H₂₇N₅O₅.C₄H₄O₄ requires

C,49.9; H,5.6; N,12.65%

Example 3

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate

25 [2-(3-Methyl-1,2,4-oxadiazol-5-yl)phenyl]carbonyl chloride (7.5g) was placed in a flask equipped with an air stirrer and ground to a powder N-[2-[4-(Hydroxymethyl)-1-piperidinyl]ethyl]methanesulphonamide (9.33g) was added and the solids intimately mixed under nitrogen for 10min at room temperature. The
 30 mixture was stirred under a stream of nitrogen at 150° for 10min. The mixture was

allowed to cool then toluene/ethanol (10:1; 110ml) was cautiously added followed by 8% sodium bicarbonate solution. The mixture was vigorously stirred, the layers were separated and the aqueous phase extracted with 10% ethanol in dichloromethane (4x100ml). The organic solutions were combined and dried and concentrated in vacuo to give a beige solid. This was purified by FCC eluting with System A (100:8:1) to give the title compound (11.83g) as fluffy off-white needles.

T.l.c. (System A 100:8:1) R_f 0.44

Example 4

- 10 [1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (Z)-2-butenedioate salt (1:1)
 [1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (11.83g) was dissolved in warm methanol/dichloromethane (50ml/25ml) and treated with a warm solution of maleic acid (2.91g) in methanol (25ml).
 15 The resultant solution was concentrated in vacuo to give a viscous gum which rapidly solidified upon standing. The beige solid was crystallised from absolute ethanol (500ml) to give the title compound (12.25g) as fluffy white microneedles, m.p. 163-164°.

Analysis Found:

C, 50.15; H, 5.7; N, 12.6;

C₁₉H₂₇N₅O₅S.C₄H₄O₄ requires

C, 49.9; H, 5.6; N, 12.65; S, 5.8%

- 20 H.p.l.c. found the material to be 99% pure.

Example 5

- [1-[2-[(Methylsulphonyl)methylamino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate
 25 To a stirred solution of [1-[2-[(methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (190mg) in dry THF (5ml) was added tetra butyl ammonium fluoride (1.10ml, 1.0M solution in THF). After 30min methyl iodide (0.03ml) was added and the suspension stirred for 2.5h. The mixture was poured into 8% sodium bicarbonate (25ml) solution, extracted with dichloromethane
 30 (4x10ml), and the combined organic layers were dried and evaporated to give a yellow

solid (414mg). The solid was purified by column chromatography using System A (300:8:1) as eluant to give a white solid (224mg). FCC using System A (400:8:1) as eluant gave the title compound (55mg) as a white solid.

T.l.c. (System A 300:8:1) Rf 0.35

5

Example 6

[1-[2-[(Methylsulphonyl)methylamino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (Z)-2-butenedioate salt (1:1)

10 [1-[2-[(Methylsulphonyl)methylamino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (55mg) was dissolved in boiling ethyl acetate (1ml) and maleic acid (17mg) in hot ethyl acetate (1ml) added. White crystals precipitated. These were filtered and dried under vacuum to give the title compound (51mg), as a white powder, m.p. 170-172°

Analysis Found:

C,50.77; H,5.91; N,12.21;

15 $C_{20}H_{29}N_5O_5 \cdot S \cdot C_4H_4O_4$ requires:

C,50.78; H,5.86; N,12.34%

Example 7

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl]carbamate

20 A solution of 2-(3-methyl-1,2,4-thiadiazol-5-yl)benzenamine (302mg) in dry acetonitrile (20ml) was cautiously added to a 0° solution of phosgene (20% in toluene, 5ml). The resulting suspension was stirred overnight at room temperature under nitrogen. The solution was concentrated in vacuo to give a white solid (0.37g), which was ground to a powder using an air stirrer. N-[2-[4-(hydroxymethyl)-1-piperidinyl]ethyl]methanesulphonamide, (450mg) was added. The two solids were stirred for 10min and
25 then lowered into an oil bath at 175° where they were stirred under nitrogen for 25min. The resultant oil was cooled and separated between sodium bicarbonate (30ml) and 10% ethanol in toluene (30ml). The aqueous suspension was extracted with 10% ethanol in dichloromethane (3x20ml).

30

The combined organic extracts were dried and concentrated in vacuo to give a brown oil (0.7g), which crystallised on standing. FCC using System A (200:8:1) as eluant gave, on concentration of the appropriate fractions, the title compound (345mg).

T.l.c. (System A, 200:8:1) Rf 0.3

5

Similarly Prepared:-

Example 8

[1-[2-(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[4-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (74mg)

10

T.l.c. (System A, 200:8:1) Rf 0.25

From 4-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzenamine (600mg) and N-[2-[4-(hydroxymethyl)-1-piperidinyl]ethyl]methanesulphonamide (790mg).

15

Example 9

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl]carbamate, maleate

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl]carbamate (345mg) was dissolved in dichloromethane (10ml). A solution of maleic acid (95mg) in warm ethyl acetate (10ml) was added. The resultant precipitate was collected by filtration and dried to give the title compound, (397mg) m.p. 139-140°.

20

Analysis: Found:

C, 48.53; H, 5.69; N, 11.89; S, 11.26;

C₁₉H₂₇N₅O₄S₂·C₄H₄O₄ requires:

C, 48.49; H, 5.49; N, 12.29; S, 11.26%

25

Example 10

[1-[2-(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[4-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate fumarate (1:1)

[1-[2-(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[4-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (74mg) was dissolved in boiling ethyl acetate (4ml) A

30

solution of maleic acid (22mg) in warm ethyl acetate (1.5ml) was added. The resultant precipitate was collected by filtration and dried in vacuo to give a solid (61mg). N.m.r. showed an aromatic impurity. For this reason the solid was cleaved with 2N sodium hydroxide (10ml). The free base was extracted with dichloromethane (3x10ml). The organic layers were dried and concentrated in vacuo to give a white powder, (54mg). The free base was dissolved in boiling ethyl acetate (3ml). A solution of fumaric acid (26mg) in warm ethyl acetate (5ml) was added. The resulting precipitate was collected by filtration and dried in vacuo to give the title compound (37mg), m.p. 174-175°.

N.m.r. shows ca. 1.8 molar equivalents fumaric acid

Analysis Found: C, 49.47; H, 5.61; N, 10.80;
 $C_{20}H_{23}N_3O_5 \cdot 1.8 C_4H_4O_4$ requires: C, 49.46; H, 5.52; N, 10.60%

Example 11

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate hydrochloride

A mixture of [4-methoxy-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbonyl chloride (500mg) and N-[2-[4-(hydroxymethyl)-1-piperidinyl]ethyl]methanesulphonamide (662mg) was heated at 150° under nitrogen for 20min. FCC with System A (250:10:1) as the eluent gave a pale yellow solid (380mg). This material was dissolved in dichloromethane:ethanol (1:1; 5ml) and treated with an excess of ethereal hydrogen chloride solution. The solvent was removed in vacuo and the residue triturated with dry ether (5x5ml) to give the title compound as a white solid (400mg), m.p. 200°.

T.l.c. (System A, 250:10:1) R_f=0.35

Example 12

[1-[2-[(Methylamino)sulphonyl]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate maleate (1:1)

4-Piperidinylmethyl [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (442mg), acetonitrile (25ml), N-methylethanesulphonamide, (172mg) and N,N-diisopropylethylamine (0.49ml) were stirred at reflux under nitrogen for 4h. The

solvent was removed under vacuum to leave a brown oil (800mg). FCC using System A (200:8:1) as eluant gave a white solid (303mg). The free base was dissolved in boiling ethyl acetate (5ml). A solution of maleic acid (86mg) in warm ethyl acetate (4ml) was added. On standing a white solid precipitated. This was collected by filtration and dried

5 in vacuo to give the title compound as a white powder, (394mg), m.p. 181-182°.

T.l.c. (System A, 200:8:1) Rf 0.45

Similarly prepared:-

Example 13

10 [1-(2-Methoxyethyl)-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate maleate (1:1) (289mg), m.p. 124-126°.

Analysis:

C, 56.6; H, 5.97; N, 11.38;

C₁₉H₂₆N₄O₄·C₄H₄O₄ requires: C, 56.43; H, 6.27; N, 11.45%

From 4-Piperidinylmethyl [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (366mg)
15 and 2-bromoethylmethyl ether (0.11ml).

Example 14

20 [1-[3-[(Methylsulphonyl)amino]propyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate maleate (1:1) (308mg), m.p. 161-162°.

Analysis Found:

C, 49.94; H, 5.87; N, 12.2;

C₂₀H₂₉N₅O₅·S·C₄H₄O₄·0.1H₂O requires:

C, 50.62; H, 5.88; N, 12.30%

Water determination, shows 0.32% w/w H₂O ~0.1 molar equivalents H₂O

From 4-Piperidinylmethyl [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (256mg)
25 and N-(3-bromopropyl)methane sulphonamide (216mg).

Example 15

30 [1-[2-(Acetyl amino)ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate di-p-toluoyl-L-tartrate

From 4-Piperidinylmethyl [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (304mg) and N-(2-chloroethyl)acetamide (0.1ml). The free base (74mg) was dissolved in boiling ethyl acetate (5ml). A solution of maleic acid (29mg) was added. On standing no precipitation occurred. The free base was reliberated by the addition of 8% sodium bicarbonate solution (20ml), extraction with dichloromethane (4x10ml), drying the combined organic layers and concentrating in vacuo to give a white solid (ca. 0.1g). This was purified by chromatography on silica using System A (200:8:1) as eluant to give the free base as a white powder, (70mg). The free base (53mg) was dissolved in methanol (5ml). A solution of di-p- toluoyl-l-tartaric acid (51mg) was added. The solution was evaporated to dryness and the glassy residue triturated with diethyl ether (20ml). Filtration and drying under vacuum gave the title compound as a white solid (75mg), m.p. >130° (dec.)

Analysis found:

C,60.21; H,5.91; N,8.59;

$C_{22}H_{27}N_5O_4 \cdot C_{20}H_{19}O_4 \cdot H_2O \cdot 0.1C_4H_{10}O$ requires: C,59.67; H,5.95; N,8.61% Water determination, shows 2.29% w/w H_2O

~1.0 molar equivalents H_2O

Example 16

N-[2-[4-[2-[[[[2-(3-Methyl-1,2,4-oxadiazol-5-yl)phenyl]amino]

carbonyl]amino]ethyl]-1-piperidinyl]ethyl]methanesulphonamide dihydrochloride

From N-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-N'-[2-(4-piperidinyl)ethyl] urea (300mg) and 2-iodoethyl-N-methylsulphonamide (341mg). The free base (215mg) was dissolved in dichloromethane (2ml) and treated with an excess of ethereal hydrogen chloride solution. The solvent was removed in vacuo and the residue triturated with dry ether (5x10ml) to give the title compound as a pale yellow solid (200mg) m.p. 178-180° T.l.c. (System A, 150:10:1) Rf 0.28

Example 17

1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate monohydrochloride

From 2-(3-methyl-1,2,4-oxadiazol-5-yl)-4-(piperidinyl)[2-(3-methyl-1,2,4-oxadiazol-5-yl) phenyl]carbamate (350mg) and 2-iodoethyl-N- methylsulphonamide (433mg). The free base (360mg) was dissolved in dichloromethane (3ml) and treated with an excess of ethereal hydrogen chloride solution. The solvent was removed in vacuo and the residue
5 triturated with dry ether (5x10ml) to give the title compound as a white solid (370mg), m.p. 219-220°
T.l.c. (System A, 250:10:1), R_f0.30.

Example 18

10 [1-(3-Amino-3-oxopropyl)-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl) phenyl]carbamate maleate (1:1)
4-Piperidinylmethyl [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (410mg), 3-chloropropionamide (142mg), N,N- diisopropylethylamine (0.48ml) and dry acetonitrile (20ml) were stirred at reflux under nitrogen for 25h. Cooling and concentration in vacuo
15 gave an orange solid (0.612g) which was purified by FCC using System A (90:10:1) as eluant to give a white solid (399mg). The free base was dissolved in boiling ethyl acetate (20ml). A solution of maleic acid (119mg) in hot ethyl acetate (3ml) was added. Concentration in vacuo followed by trituration of the residue in tetrahydrofuran (20ml), filtration and drying gave a brown solid (378mg) which was again triturated with
20 tetrahydrofuran (15ml). Filtration and drying in vacuo gave a white solid (312mg). Recrystallisation from tetrahydrofuran (10ml) and ethanol (3.5ml) gave, on standing and after addition of cyclohexane (ca. 5ml), the title compound as white crystals, (255mg).

Analysis Found: C, 54.47; H, 6.33; N, 12.39;
C₁₉H₂₃N₅O₄ · C₄H₄O₄ requires: C, 54.86; H, 5.81; N, 13.91%

25 Water analysis, shows 0.95% w/w H₂O -0.27molar equivalents.

The title compound was cleaved by 8% sodium bicarbonate solution (15ml) and the free base isolated by extracting the aqueous layer with dichloromethane (4x10ml), drying the combined organic layers and concentrating in vacuo to give a white solid (158mg). This was dissolved in warm ethyl acetate (10ml). A solution of maleic acid (50mg) in hot
30 tetrahydrofuran (1ml) was added. The resulting solution was concentrated in vacuo to

give an oil which was triturated with tetrahydrofuran to give a white solid. This was filtered, washed with cyclohexane and dried under vacuum to give a white solid (143mg). N.m.r. showed ca. 1 molar equivalent of tetrahydrofuran. To remove residual tetrahydrofuran, the salt was triturated with diethyl ether (20ml). Filtration, washing with
 5 cyclohexane and drying under vacuum gave a white solid (97mg) M.p. 138-139°

Analysis Found:

C, 55.32; H, 5.97; N, 13.93;

C₁₇H₂₅N₃O₄ · C₄H₄O₄ requires:

C, 54.86; H, 5.81; N, 13.91%

Example 19

10 [1'-(Methylsulphonyl)[1,4'-bipiperidin]-4-yl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate maleate (1:1)

To 4-Piperidinylmethyl [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (366mg), was added N-(4-oxopiperidiny)methanesulphonamide (180mg), dichloroethane (15ml) and glacial acetic acid (0.07ml). The yellow solution was stirred under nitrogen and
 15 sodium triacetoxyborohydride (355mg) cautiously added. The resulting suspension was stirred under nitrogen for 48h and another quantity of the borohydride (156mg) added. After stirring for a further 24h, 8% sodium bicarbonate solution (25ml) was added. The layers were separated and the aqueous layer extracted with dichloromethane (5x10ml). The combined organic extracts were dried and concentrated in vacuo to give a cream
 20 solid (604mg), which was purified by FCC using System A (30:8:1) as eluant to give a white solid (249mg). This was further purified by FCC using System A (200:8:1) as eluant to give a white solid (185mg) which was further purified on silica using ethyl acetate:ethanol:aqueous ammonia (100:8:1) as eluant to give the free base of the title compound as a white solid, (54mg).

25 T.l.c. (System A, 30:8:1) R_f 0.36

The free base was dissolved in boiling ethyl acetate (ca. 3ml). Maleic acid (13.7mg) was added and the mixture left standing overnight. Filtration, washing with fresh ethyl acetate (5ml) and drying in vacuo gave the title compound (36mg), m.p. 186-187°

Analysis Found:

C, 52.11; H, 5.9; N, 11.51;

30 C₂₂H₂₁N₃O₄ · 0.95C₄H₄O₄ · 0.04H₂O requires:

C, 52.56; H, 6.13; N, 11.88%

Water analysis found: 0.12% w/w H₂O -0.04 molar equivalents H₂O

Example 20

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[5-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate maleate (1:1)

5 A solution of 5-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzenamine (971mg) in sieve-dried acetonitrile (15ml) was added dropwise to a solution of phosgene at 0° (20% in toluene, 14ml). The white suspension was stirred under N₂ for 5h. Concentration in vacuo gave a white solid, to which was added dry dichloromethane (30ml) followed by a
10 solution of N-[2-[4-(Hydroxymethyl)-1-piperidinyl]ethyl]methanesulphonamide (1.615g) in sieve-dried dichloromethane (30ml). The resulting suspension was stirred under nitrogen at room temperature for 24h. 8% sodium bicarbonate (60ml) was added and the layers separated. The aqueous layer was extracted with dichloromethane (4x10ml). The combined organic layers were dried, filtered and concentrated in vacuo to give a white
15 foam (1.9g). FCC using System A (200:8:1) as eluant produced a white solid (0.35g), which was further purified by FCC using ethyl acetate:ethanol:aqueous ammonia (200:8:1) as eluant to give the free base of the the title compound, as a white powder (173mg).

T.l.c. (System A, 200:8:1) R_f 0.25

20 The free base was dissolved in boiling ethyl acetate (5ml) and a solution of maleic acid (47mg) in warm ethyl acetate (3ml) was added. Standing, filtration and drying under vacuum gave the title compound as a white solid (168mg), m.p. 165-167°.

Analysis Found:

C, 48.16; H, 5.25; N, 12.19;

C₁₉H₂₆FN₅O₅S.C₄H₄O₄ requires:

C, 48.33; H, 5.29; N, 12.25%

25

Example 21

N-[2-[4-[[[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]amino]carbonyl]amino]methyl]-1-piperidinyl]ethyl]methanesulphonamide maleate (1:1)

30 A solution/suspension of [2-(3-Methyl-1,2,4-oxadiazol-5-yl)phenyl]carbonyl chloride (129mg) in acetonitrile (30ml) was stirred at room temperature under a nitrogen

atmosphere. N-[2-[4-(aminomethyl)-1-piperidinyl]ethyl]methanesulphonamide (140mg) was added in acetonitrile (5ml) and the resulting solution stirred overnight. The resulting white suspension was reduced to dryness under vacuo before purifying by FCC with System A (90:10:1) as the eluent, giving the free base of the title compound as a white solid (61mg). T.l.c. (System A, 90:10:1) Rf 0.38. The free base was dissolved in methanol (5ml) and maleic acid (15mg), in methanol (3ml) was added. The solvent was removed in vacuo and the residual oil was triturated with ether to yield a the title compound as a white solid (74mg) 67-69°.

Analysis Found:

C,48.77; H,5.94; N,14.6;

10 C₁₉H₂₂N₆O₄S.C₄H₄O₄.H₂O requires:

C,48.41; H,6.01; N,14.73%

Example 22

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate maleate (1:1)

15 Sodium hydride (60% in oil; 73mg) was added to a solution of 2- cyclopropylacetamide oxime (146mg) in distilled tetrahydrofuran (20ml) containing 4 molecular sieves (6 pellets) under a nitrogen atmosphere at room temperature. The yellow suspension was refluxed for 0.75h, cooled and a further portion of sodium hydride (68mg) added, followed by a solution of methyl-2-[[[1-[2-[(methylsulphonyl)amino]ethyl]-4-piperidinyl] methoxy]carbonyl]amino]benzoate (231mg) in distilled tetrahydrofuran (10ml). The solution was refluxed for 4.5h, then allowed to cool. Ethanol (10ml) was added and the resulting suspension concentrated in vacuo to give a yellow solid. FCC using System A (200:8:1) as eluant gave the free base of the title compound (40mg). T.l.c. (System A, 200:8:1) Rf 0.25.

25 The free base was dissolved in warm ethyl acetate (2ml) and a solution of maleic acid (13mg) in warm ethyl acetate (2ml) was added. The resulting precipitate was collected by filtration and dried in vacuo to give the title compound as a yellow powder, (43mg), m.p. 160-161°.

Analysis Found:

C,51.42; H,5.74; N,11.89

30 C₂₁H₂₉N₆O₄S.C₄H₄O₄ requires:

C,51.8; H,5.74; N,12.08%

Similarly prepared:-

Example 23

5 [1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate maleate (1:1), (59mg), m.p. 169-170°.

Analysis Found: C, 54.29; H, 5.53; N, 10.77;

$C_{24}H_{29}N_5O_5 \cdot S \cdot C_4H_4O_4 \cdot 0.3H_2O$ requires: C, 54.15; H, 5.45; N, 11.28%

Water determination Found: 0.86% w/w H_2O , -0.3 molar equivalents H_2O .

10 From benzamide oxime (92mg) and methyl-2-[[[1-[2-[(methylsulphonyl)amino]ethyl]-4-piperidinyl]methoxy]carbonyl]amino]benzoate (167mg). Via free base of title compound (60mg)

T.l.c. (System A, 200:8:1) Rf 0.3.

Example 24

15 [1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]phenyl]carbamate maleate (1:1) (126mg), m.p. 171-172°;

Analysis Found: C, 51.01; H, 6.04; N, 11.76;

$C_{21}H_{31}N_5O_5 \cdot S \cdot C_4H_4O_4 \cdot 0.1H_2O$ requires: C, 51.47; H, 6.08; N, 12.00%

Water determination, found 0.27% H_2O -0.1 molar equivalents H_2O

20 From N-hydroxy-2-methylpropanimidamide (102mg) and methyl-2-[[[1-[2-[(methylsulphonyl)amino]ethyl]-4-piperidinyl]methoxy]carbonyl]amino]benzoate (230mg). Via the free base (124mg).

T.l.c. (System A, 200:8:1) Rf 0.3

25 Example 25

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-[3-(phenylmethyl)-1,2,4-oxadiazol-5-yl]phenyl]carbamate maleate (1:1) (65mg) m.p. 143-144°.

Analysis Found: C, 54.7; H, 5.5; N, 10.95;

$C_{23}H_{31}N_5O_5 \cdot S \cdot C_4H_4O_4 \cdot 0.15H_2O$ requires: C, 55.1; H, 5.62; N, 11.08%

30 Water determination showed ca. 0.40% w/w H_2O

-0.15 molar equivalents present

From 2-phenylacetamideoxime (120mg) methyl-2-[[[1-[2-[(methylsulphonyl) amino]ethyl]-4-piperidinyl]methoxy]carbonyl]amino]benzoate (253 mg). Via free base (80mg).

5

Example 26

1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate

From acetamide oxime (22mg) and methyl-2-[[[1-[2-[(methylsulphonyl) amino]ethyl]-4-piperidinyl] methoxy]carbonyl]amino]benzoate (100mg) to give free base (52mg) as a white solid. (Characterisation as for Example 1).

10

Example 27

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]phenyl]carbamate monohydrochloride

15

From N-hydroxy-2,2-dimethylpropanimidamide (85mg) and methyl-2-[[[1-[2-[(methylsulphonyl)amino]ethyl]-4-piperidinyl]methoxy]carbonyl]amino] benzoate (250mg) to give free base as a cream solid (144mg)

T.l.c (System A, 95:5:0.5)

The free base was dissolved in dichloromethane (5ml) and treated with ethereal hydrochloric acid. Concentration and trituration with ether afforded the title compound as a cream solid (120mg), m.p. 233-235°

20

Analysis Found: C, 51.0; H, 6.7; N, 13.5; C₂₇H₃₃N₅O₅.S.HCl

Requires: C, 51.2; H, 6.7; N, 13.6%

25

Water analysis contains 0.35% H₂O by weight.

Example 28

[1-(1-Methylethyl)-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate

30

N-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-N'-[2-(4-piperidinyl)ethyl]urea (450mg) (287mg), analar grade acetone (0.075ml) and glacial acetic acid (0.07ml) were stirred in dichloromethane (20ml) under nitrogen. Sodium triacetoxyborohydride (269mg) was cautiously added. The cloudy liquid was stirred and after 49h a further quantity of acetone (0.05ml) was added. After 68h sodium triacetoxyborohydride (100mg) was added. After 120h 8% sodium bicarbonate solution was added. The resulting layers were separated and the aqueous layer extracted with dichloromethane (4x10ml). The combined organic layers were concentrated to give a white solid (244mg). This was purified by FCC using System A (90:10:1), yielding the title compound as a white powder (130mg). T.l.c. (System A 90:10:1) Rf 0.55.

Example 29

[1-(1-Methylethyl)-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl] carbamate maleate (1:1)

To a warm solution of [1-(1-methylethyl)-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (120mg) in the minimum amount of ethyl acetate was added a solution of maleic acid (36.9mg) in the minimum amount of warm methanol (2ml). Concentration in vacuo left a white oily residue which was triturated twice in ether (10ml). The resulting white powder was filtered and dried in vacuo to yield the title compound as a light brown solid (107mg), m.p. 89- 93°.

Analysis Found: C,57.39; H,6.41; N,11.2;

C₁₉H₂₆N₄O₃·C₄H₄O₄·2C₄H₁₀O·0.35H₂O requires:

C,57.68; H,6.65; N,11.3

Water analysis found 0.71% w/w H₂O (i.e. ca. 0.2 molar equivalents H₂O)

Example 30

1-Methyl-4-[[[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl] amino]carbonyloxy]methyl]-1-[2-[(methylsulphonyl)amino] ethyl]piperidinium iodide

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl)methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (136mg) was dissolved in sieve-dried dichloromethane (3ml). Methyl iodide (0.9ml) was added and the solution stirred for 48h. The resulting white residue was triturated with cyclohexane (10ml) and dried in vacuo to give a white solid (145mg). Trituration with ethyl acetate (3x10ml) gave, on filtration and drying in vacuo, the title compound as a white solid (104mg), 190° (dec.).

Analysis Found:

C,41.13; H,5.24; N,11.88;

C₂₀H₃₀N₅O₃S requires:

C,41.46; H,5.22; N,11.68%

10 Example 31

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl)methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate N-oxide

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl)methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate(600mg) was dissolved in 8% sodium bicarbonate solution, and the free base extracted with dichloromethane (4x10ml). Concentration in vacuo gave a white solid (460mg). To this was added a further portion of the free base (136mg). The combined free base was dissolved in sieve-dried chloroform (25ml), m-chloroperbenzoic acid (589mg) was cautiously added and the resulting suspension stirred under nitrogen for 20h at room temperature. 2N hydrochloric acid (30ml) was added. The layers were separated, the aqueous layer washed with chloroform (2x30ml) and the combined organic layers back-extracted with water (10ml). The combined aqueous layers were concentrated in vacuo to give a white solid (0.675g). FCC using System A (25:8:1) as eluant gave a solid which was further purified by FCC using System A (50:8:1) as eluant to give the title compound as a white powder (270mg), m.p. >185° (dec).

25 Mass spectrum shows [MH]⁺ at 454.2

T.l.c. (System A, 25:8:1) R_f 0.4.

Example 32

N-[2-[4-[[[[2-(5-Methyl-1,2,4-oxadiazol-3-yl)phenyl]amino]carbonyl]amino]methyl]-1-piperidinyl]ethyl]methanesulphonamide monohydrochloride

A solution of N-[2-[4-(aminomethyl)-1-piperidinyl]ethyl]methanesulphonamide (270mg) in acetonitrile (10ml) was added to a stirred solution of [2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl] carbamoyl chloride (250mg) in acetonitrile (30ml) and stirred at room temperature under a nitrogen atmosphere for 22h and then at 60° for 22h. The reaction mixture was then concentrated to give a cream solid (490mg). The solid was purified by FCC eluting with ethyl acetate followed by System A (90:10:1) to yield a cream solid (66mg). This was dissolved in methanol and ethereal hydrogen chloride was added. Concentration followed by trituration with ethyl acetate gave a solid which was further purified by FCC using System A (90:10:1) as eluant. The resulting solid (32mg) was dissolved in dichloromethane/methanol, treated with ethereal hydrogen chloride and triturated with ethyl acetate to give the title compound as a white solid (12mg).

N.m.r. \square (DMSO)

4.65 (1H, brs), 8.885 (1H, s), 8.275 (1H, brd) 7.975 (1H, brd) 7.42 - 7.505 (2H, dt & t), 7.375 (1H, brt), 7.125 (1H, dt), 3.525 (2H, brd) 2.8-3.45 (11H, 3 x m), 1.865 (2H, brd), 1.75 (1H, brm) 1.455 (2H, brq).

Example 33

[1-[2-[(Methylsulphonyl)methylamino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate maleate (1:1)

To a stirred solution of [1-[2-[(methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate (190mg) in dry tetrahydrofuran (5ml) was added tetrabutylammonium fluoride (1.10ml, 1.0M solution in tetrahydrofuran). After 30min methyl iodide (0.03ml) was added and the suspension stirred for 2.5h. Pouring into 8% sodium bicarbonate (25ml) solution, extracting with dichloromethane (4x10ml) and drying the combined organic layers gave, on filtration and concentration in vacuo, a yellow solid (0.414g). FCC using System A (200:8:1) as eluant gave a white solid (224mg). Further purification by FCC using System A (300:8:1) as eluant gave a white solid (144mg). Further FCC using System A (400:8:1) gave the free base of the title compound as a white solid (55mg).

T.l.c (System A 300:8:1) Rf 0.35

The free base (55mg) was dissolved in boiling ethyl acetate (1ml) and maleic acid (17mg) in hot ethyl acetate (1ml) added. White crystals precipitated. These were filtered and dried under vacuum to give the title compound as a white powder (51mg), m.p. 170- 172°

5 Analysis Found: C, 50.77; H, 5.91; N, 12.21;
 $C_{20}H_{29}N_3O_3 \cdot C_4H_4O_4$ requires: C, 50.78; H, 5.86; N, 12.34%

Example 34

N-(3-Methyl-1,2,4-oxadiazol-5-yl)-N'-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]urea

10 A mixture of [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbonyl chloride (1.0g) and 4-(2-aminoethyl)-1-benzylpiperidine (1.38g) was stirred at 150° under nitrogen for 15 min. FCC with System A (250:10:1) as the eluent gave the title compound as a white solid (1.47g) m.p. 138-9°

T.l.c. (System A 250:10:1), Rf=0.42

15

Similarly prepared:-

Example 35

1-(Phenylmethyl)-4-piperidinyl [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate

20 (1.18g)

T.l.c. (System a 500:10:1) Rf=0.50

From [2-(3-Methyl-1,2,4-oxadiazol-5-yl)phenyl]carbonyl chloride (1.0g) and 1-benzyl-4-hydroxypiperidine (1.2g). A sample of the free-base (160mg) was dissolved in dry dichloromethane (2ml) and treated with an excess of ethereal hydrogen chloride solution. The solvent was removed in vacuo and the residue triturated with dry ether (5x5ml) to give the monohydrochloride of the title compound as a white solid (163mg), m.p. 240-242°

25

Analysis Found: C, 61.2; H, 6.0; N, 12.8;
 $C_{22}H_{27}N_3O_3 \cdot HCl$ requires: C, 61.6; H, 5.9; N, 13.1%

30

Example 36

[1-[(Phenylmethyl)-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]
carbamate

A solution/suspension of [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbonyl chloride
5 (1.177g) in acetonitrile (50ml) was stirred under a nitrogen atmosphere.
1-benzyl-4-hydroxymethyl piperidine (1.53g) in dry dichloromethane (5ml) was added and
the resulting solution stirred at room temperature overnight. The mixture was reduced to
dryness under vacuo to give a white solid (3.71). The solid was washed with 2N
hydrochloric acid (100ml) and extracted with ether (2x100ml). The aqueous was
10 are-basified with sodium bicarbonate (pH8) and the product extracted into
dichloromethane (3x500ml). The solvent was removed under vacuo yielding a white solid
which was further purified by FCC with 15% methanol in toluene as eluent, giving the
title compound as a pale yellow solid (1.53g), m.p. 105-107°.

T.l.c. (15% methanol in toluene) Rf 0.74

15

Example 37

[1-[2-(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-
yl)phenyl]carbamate

Methanesulphonyl chloride (0.02ml) was added to a stirred solution of
20 1-[(2-aminoethyl-4-piperidinyl)methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]
carbamate (100mg) and pyridine (0.05ml) in dry dichloromethane (2.5ml) under nitrogen.
After 1.5h water (10ml) was added and the mixture extracted with dichloromethane
(3x5ml). The combined extracts were dried, filtered and evaporated to give a yellow oil
(~125mg). FCC with System A (250:10:1) as the eluent gave the title compound as a
25 white solid (68mg) m.p. 126-7°.

The following salt was prepared according to conventional procedures:-

Example 38

[1-[2-(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-
30 yl)phenyl]carbamate, methanesulphonate salt

m.p. 165-167°, ν_{max} (Nujol) 1741, 1597, 1044, 748, 552 cm^{-1} .

5

Biological Data

The antagonism of 5-HT at 5-HT₄ receptors by compounds of the invention has been demonstrated in vitro using the rat oesophagus test as described hereinbefore. Thus, for example, the compounds of the following examples gave the following pkb values

10

	<u>Compound of</u> <u>Example</u>	<u>pkb</u>
15	1	10.8
	11	8.1
	13	10.0
	20	8.9
	21	7.8
	33	8.6

20

The compounds of the invention exhibited no apparent adverse or toxic effects when administered to rats in vivo. Thus the compound of Example 1 exhibited no apparent adverse or toxic effects when administered intraperitoneally to conscious rats up to doses of 1mg/kg.

25

30

Pharmacy ExamplesExample 1 - Tablets

a) Compound of the invention	5.0mg
Lactose	95.0mg
Microcrystalline Cellulose	90.0mg
Cross-linked polyvinylpyrrolidone	8.0mg
Magnesium Stearate	<u>2.0mg</u>
Compression weight	200.0mg

The compound of the invention, microcrystalline cellulose, lactose and cross linked polyvinylpyrrolidone are sieved through a 500 micron sieve and blended in a suitable mixer. The magnesium stearate is sieved through a 250 micron sieve and blended with the active blend. The blend is compressed into tablets using suitable punches.

b) Compound of the invention	5.0mg
Lactose	165.0mg
Pregelatinised Starch	20.0mg
Cross-linked polyvinylpyrrolidone	8.0mg
Magnesium Stearate	<u>2.0mg</u>
Compression weight	200.0mg

The compound of the invention, lactose and pregelatinised starch are blended together and granulated with water. The wet mass is dried and milled. The magnesium stearate and cross-linked polyvinylpyrrolidone are screened through a 250 micron sieve and blended with the granule. The resultant blend is compressed using suitable tablet punches.

Example 2 - Capsules

a) Compound of the invention	5.0mg
Pregelatinised Starch	193.0mg
Magnesium Stearate	<u>2.0mg</u>
Fill weight	200.0mg

The compound of the invention and pregelatinised starch are screened through a 500 micron mesh sieve, blended together and lubricated with magnesium stearate, (meshed through a 250 micron sieve). The blend is filled into hard gelatine capsules of a suitable size.

b) Compound of the invention	5.0mg
Lactose	177.0mg
Polyvinylpyrrolidone	8.0mg
Cross-linked polyvinylpyrrolidone	8.0mg
Magnesium Stearate	<u>2.0mg</u>
Fill weight	200.0mg

The compound of the invention and lactose are blended together and granulated with a solution of polyvinylpyrrolidone. The wet mass is dried and milled. The magnesium stearate and cross-linked polyvinylpyrrolidone are screened through a 250 micron sieve and blended with the granules. The resultant blend is filled into hard gelatine capsules of a suitable size.

Example 3 - Syrup

a) Compound of the invention	5.0mg
Hydroxypropyl Methylcellulose	45.0mg
Propyl Hydroxybenzoate	1.5mg
Butyl Hydroxybenzoate	0.75mg
Saccharin Sodium	5.0mg
Sorbitol Solution	1.0ml

Suitable Buffers	qs
Suitable flavours	qs
Purified Water to	10.ml

The hydroxypropyl methylcellulose is dispersed in a portion of hot purified water together with the hydroxybenzoates and the solution is allowed to cool to room temperature. The saccharin sodium flavours and sorbitol solution are added to the bulk solution. The compound of the invention is dissolved in a portion of the remaining water and added to the bulk solution. Suitable buffers may be added to control the pH in the region of maximum stability. The solution is made up to volume, filtered and filled into suitable containers.

Example 4 - Injection Formulation

	% w/v
Compound of the invention	1.00
Water for injections B.P. to	100.00


Sodium chloride may be added to adjust the tonicity of the solution and the pH may be adjusted to that of maximum stability and/or to facilitate solution of the compound of the invention using dilute acid or alkali or by the addition of suitable buffer salts. Antioxidants and metal chelating salts may also be included.

The solution is prepared, clarified and filled into appropriate sized ampoules sealed by fusion of the glass. The injection is sterilised by heating in an autoclave using one of the acceptable cycles. Alternatively the solution may be sterilised by filtration and filled into sterile ampoules under aseptic conditions. The solution may be packed under an inert atmosphere of nitrogen.

SUBSTITUTE SHEET

1. Compounds of formula (I)

5




10 wherein R^1 represents a hydrogen or a halogen atom, or a C_{1-6} alkyl, C_{1-6} alkoxy or hydroxy group;

R^2 represents an oxadiazole or thiadiazole ring substituted by a group selected from C_{1-6} alkyl, C_{3-7} cycloalkyl, $-CH_2C_{2-3}$ alkenyl, $-CH_2C_{2-3}$ alkynyl, phenyl or benzyl;

X represents NH or an oxygen atom;

m represents zero, 1 or 2;

15 R^3 represents C_{1-6} alkyl, benzyl, $-(CH_2)_nR^4$ or



20 R^4 represents a group selected from cyano, hydroxyl, C_{1-6} alkoxy, phenoxy, $C(=O)C_{1-6}$ alkyl, $C(=O)C_6H_5$, $-CONR^6R^7$, $-NR^6COR^7$, $-SO_2NR^6R^7$ or $-NR^6SO_2R^7$ (wherein each of R^6 and R^7 independently represent a hydrogen atom, a C_{1-6} alkyl or phenyl group);

n represents 2 or 3;

R^5 represents COR^8 or SO_2R^8 (wherein R^8 represents a hydrogen atom, a C_{1-6} alkyl or phenyl group);

25 and quaternary ammonium derivatives, piperidine N-oxides and pharmaceutically acceptable salts and solvates thereof.

2. A compound as claimed in Claim 1 in which X is an oxygen atom.

3. A compound as claimed in Claim 1 or Claim 2 in which m is 1.

4. A compound as claimed in any of Claims 1 to 3 in which R^3 is a group $-(CH_2)_nR^4$

30 5. A compound as claimed in Claim 4 in which n is 2.

6. A compound a claimed in Claim 4 or Claim 5 in which R⁴ is a group NR⁶SO₂R⁷.

7.

[1-[2-[(Methylsulphonyl)methylamino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl) phenyl]carbamate;

5

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-thiadiazol-5-yl)phenyl]carbamate;

10

[1-[2-(Methylsulphonyl)amino]ethyl]-4-piperidinyl]methyl[4-methyl- 2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

[1-[2-[(Methylamino)sulphonyl]ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

15

[1-(2-Methoxyethyl)-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl] carbamate;

[1-[3-[(Methylsulphonyl)amino]propyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

20

[1-[2-(Acetylamino)ethyl]-4-piperidinyl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl) phenyl]carbamate di-p-toluoyl-1-tartrate;

25

N-[2-[4-[2-[[[2-(3-Methyl-1,2,4-oxadiazol-5-yl)phenyl]amino]carbonyl]amino]ethyl] -1-piperidinyl]ethyl]methanesulphonamide;

1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidinyl[2-(3-methyl-1,2,4-oxadiazol-5-yl) phenyl]carbamate;

30

[1-(3-Amino-3-oxopropyl)-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

5 [1'-(Methylsulphonyl)[1,4'-bipiperidin]-4-yl]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidiny]methyl[5-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

10 N-[2-[4-[[[2-(3-Methyl-1,2,4-oxadiazol-5-yl)phenyl]amino]carbonyl]amino]methyl]-1-piperidiny]ethyl]methanesulphonamide;

15 [1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidiny]methyl[2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidiny]methyl[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

20 [1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidiny]methyl[2-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]phenyl]carbamate;

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidiny]methyl[2-[3-(phenylmethyl)-1,2,4-oxadiazol-5-yl]phenyl]carbamate;

25 1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

[1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidiny]methyl[[2-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]phenyl]carbamate monohydrochloride;

30

[1-(1-Methylethyl)-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]
carbamate;

5 [1-(1-Methylethyl)-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]
carbamate;

N-[2-[4-[[[[2-(5-Methyl-1,2,4-oxadiazol-3-yl)phenyl]amino]carbonyl]amino]methyl]
-1-piperidiny]ethyl]methanesulphonamide;

10 [1-[2-[(Methylsulphonyl)methylamino]ethyl]-4-piperidiny]methyl[2-(3-methyl-1,2,4-
oxadiazol-5-yl)phenyl]carbamate;

N-(3-Methyl-1,2,4-oxadiazol-5-yl)-N'-[2-[1-(phenylmethyl)-4-piperidiny]ethyl]urea;

15 1-(Phenylmethyl)-4-piperidiny [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]carbamate;

[1-[(Phenylmethyl)-4-piperidiny]methyl[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]
carbamate;

20 and pharmaceutically acceptable salts thereof.

8. [1-[2-[(Methylsulphonyl)amino]ethyl]-4-piperidiny]methyl[2-(3-methyl-1,2,4-
oxadiazol-5-yl)phenyl]carbamate;

and pharmaceutically acceptable salts thereof.

25

9. The compound of Claim 8 in the form of its butenedioate salt.

10. The compound of Claim 9 in the form of its methanesulphonate salt.

30

11. A compound as claimed in any of Claims 1 to 10 for use in therapy.


12. A method for treatment of conditions mediated by 5-hydroxytryptamine, in particular conditions capable of amelioration by antagonism of 5-HT₁ receptors, comprising administration of an effective amount of a compound of formula (I) as claimed in any one of Claims 1 to 10.

13. The use of a compound as claimed in any one of Claims 1 to 10 in the preparation of a medicament for use in the treatment of conditions mediated by 5-hydroxytryptamine, in particular conditions capable of amelioration by antagonism of 5-HT₁ receptors.


14. A pharmaceutical composition comprising a compound as claimed in any one of Claims 1 to 10 together with a pharmaceutically acceptable carrier.

15. A process for the preparation of a compound of formula (I) as claimed in Claim 1, which process comprises :-

(A) reacting a compound of formula (II) or (III):




25 or a protected derivative thereof, wherein Y represents a leaving atom or group, with a compound of formula (IV) :



30 where M is NH₂, OH or an activated derivative thereof ;

SUBSTITUTE SHEET

(B) alkylating a compound of formula (V) :



or a protected derivative thereof, with a compound of formula (VIa) or (VIb):




wherein L represents a leaving atom or group and R^{4a} is an electron withdrawing group,
or a protected derivative thereof, in the presence of a base; or

reacting a compound of formula (V) with a compound of formula (VIc)




in the presence of a reducing agent;

(C) reacting a compound of formula (VII)




25 where Z is C₁₋₆alkoxy with a compound of formula (VIII)




where R⁹ is a substituent as defined for R², in the presence of a strong base such as sodium hydride;

30 (D) reacting a compound of formula (IX)



where R⁹ is as defined above;

10 (E) reacting a compound of formula (X)



with a compound (XI)



20 where hal is a halogen atom, in the presence of a base;

(F) converting a compound of formula (I) into another compound of formula (I);

25 (G) removing any protecting groups from a protected form of a compound of formula (I).

INTERNATIONAL SEARCH REPORT

PCT/EP 93/00779

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5	C07D413/12; A61K31/445	C07D413/14; C07D417/12; A61K31/41
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07D ; A61K	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
P,A	EP,A,0 526 313 (PIERRE FABRE MEDICAMENT) 3 February 1993 see the whole document ---	1-15
P,A	EP,A,0 516 520 (PIERRE FABRE MEDICAMENT) 2 December 1992 see the whole document ---	1-15
Y	EP,A,0 419 397 (A/S FERROSAN) 27 March 1991 cited in the application see claims 1,2 ---	1,4,5,7, 11-14
A	EP,A,0 323 077 (JOHN WYETH & BROTHER LIMITED) 5 July 1989 see the whole document ---	1-15
-/--		
<p>* Special categories of cited documents :¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
16 JULY 1993		11. 08. 93
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		HARTRAMPF G.W.

Form PCT/ISA/210 (second sheet) (January 1993)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	EP,A,0 007 184 (AMERICAN HOME PRODUCTS CORPORATION) 23 January 1980 see claims 1-7 ---	1-15
Y	BR. J. PHARMACOL. vol. 103, 1991, pages 1067 - 1072 REEVES JJ ET AL. 'Investigation into the 5-hydroxytryptamine receptor mediating smooth muscle relaxation in the rat oesophagus' cited in the application see the whole document ---	1,4,5,7, 11-14
A	CHEMICAL ABSTRACTS, vol. 93, no. 11, 15 September 1980, Columbus, Ohio, US; abstract no. 106809f, ARCHIBALD J L ET AL. 'Antihypertensive ureidopiperidines' page 25 ;column 1 ; see abstract & J. MED. CHEM. (JMCMAR,00222623); 80; VOL.23 (8); PP.857-61 ---	1-15
A	CHEMICAL ABSTRACTS, vol. 70, no. 3, 20 January 1969, Columbus, Ohio, US; abstract no. 11519x, NILSSON J L G ET AL. 'Carbanilic acid esters of cyclic amino alcohols. II. Esters of pyrrolidiny- and piperidylcarbinols as local anesthetics' page 265 ;column 2 ; see abstract & ACTA PHARM. SUECICA (APSXAS); 68; VOL.5 (3); PP.219-26 -----	1-15

Form PCT/ISA/210 (extra sheet) (January 1985)

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9300779
SA 72525

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

16/07/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0526313	03-02-93	FR-A- 2679555	29-01-93
EP-A-0516520	02-12-92	FR-A- 2677019	04-12-92
EP-A-0419397	27-03-91	AU-A- 6341490	08-04-91
		CA-A- 2066696	09-03-91
		WO-A- 9103475	21-03-91
		EP-A- 0491770	01-07-92
EP-A-0323077	05-07-89	AU-A- 2670288	29-06-89
		DE-A- 3864807	17-10-91
		EP-A- 0361629	04-04-90
		GB-A- 2213816	23-08-89
		GB-A- 2225574	06-06-90
		JP-A- 1203365	16-08-89
		US-A- 4983600	08-01-91
		US-A- 5106843	21-04-92
EP-A-0007184	23-01-80	US-A- 4224242	23-09-80
		AT-T- 1282	15-07-82
		AU-B- 519836	24-12-81
		AU-A- 4828479	10-01-80
		CA-A- 1109487	22-09-81
		GB-A, B 2025406	23-01-80
		SU-A- 1344245	07-10-87
		SU-A- 1367855	15-01-88
		WO-A- 8000151	07-02-80
		US-A- 4348413	07-09-82

EPO FORM P079

For more details about this annex : see Official Journal of the European Patent Office, No. 12/92